GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kopran Ltd (NSE:KOPRAN) » Definitions » EV-to-FCF

Kopran (NSE:KOPRAN) EV-to-FCF : (As of Dec. 13, 2024)


View and export this data going back to 1999. Start your Free Trial

What is Kopran EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Kopran's Enterprise Value is ₹11,072 Mil. Kopran's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 was ₹0 Mil. Therefore, Kopran's EV-to-FCF for today is .

The historical rank and industry rank for Kopran's EV-to-FCF or its related term are showing as below:

NSE:KOPRAN' s EV-to-FCF Range Over the Past 10 Years
Min: -132   Med: 0   Max: 44.4
Current: -86.8

During the past 13 years, the highest EV-to-FCF of Kopran was 44.40. The lowest was -132.00. And the median was 0.00.

NSE:KOPRAN's EV-to-FCF is ranked worse than
100% of 551 companies
in the Drug Manufacturers industry
Industry Median: 25.85 vs NSE:KOPRAN: -86.80

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2024-12-13), Kopran's stock price is ₹205.93. Kopran's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was ₹10.960. Therefore, Kopran's PE Ratio (TTM) for today is 18.79.


Kopran EV-to-FCF Historical Data

The historical data trend for Kopran's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kopran EV-to-FCF Chart

Kopran Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.63 14.61 -18.80 -22.22 -100.09

Kopran Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - -100.09 - -

Competitive Comparison of Kopran's EV-to-FCF

For the Drug Manufacturers - General subindustry, Kopran's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kopran's EV-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kopran's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Kopran's EV-to-FCF falls into.



Kopran EV-to-FCF Calculation

Kopran's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=11072.271/0
=

Kopran's current Enterprise Value is ₹11,072 Mil.
Kopran's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kopran  (NSE:KOPRAN) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Kopran's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=205.93/10.960
=18.79

Kopran's share price for today is ₹205.93.
Kopran's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹10.960.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Kopran EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Kopran's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Kopran Business Description

Traded in Other Exchanges
Address
Dr. E. Moses Road, 1076, Parijat House, Worli, Mumbai, MH, IND, 400 018
Kopran Ltd is an Indian based pharmaceutical company. It is engaged in manufacturing of Formulation (Finished Dosage Form) and Active Pharmaceutical Ingredients (API) i.e., Pharmaceuticals. It manufactures dosage forms including, tablets, capsules, dry powder, suspension, and injectables. Some of its product range includes antibiotics, cardiovascular, anti-diabetes, respiratory, pain management, and gastrointestinal. Geographically, it has a presence in India; South Africa; Ethiopia; Zambia; Egypt; Jordan and Rest of World.

Kopran Headlines

No Headlines